BSX

Boston Scientific, Medtronic approved for new atrial fibrillation products

Boston Scientific Corp. (NYSE:BSX) and Medtronic Inc. (NYSE:MDT) both announced regulatory approvals for new products that will expand their atrial fibrillation treatment offerings. Natick, Mass.-based Boston Scientific won CE Mark approval for its Blazer open-irrigated, a radiofrequency ablation (RFA) catheter for treating atrial fibrillation and other arrhythmias. The new open-irrigated catheter integrates the company’s Blazer […]

By MassDevice Staff

Devices & Diagnostics

Boston Scientific mocks Medtronic, St. Jude Medical cardiac products

Perhaps it was the room full of stock analysts at the posh Intercontinental Hotel in Boston that got him going, or maybe it was just some gamesmanship before this week’s Heart Rhythm Society meeting, but Boston Scientific Corp. (NYSE:BSX) CEO Ray Elliot threw some elbows Monday. Elliot, speaking at an investor’s conference two days prior […]

By MassDevice Staff

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Devices & Diagnostics

Boston Scientific: Stents will make up for soft CRM market

Boston Scientific Corp. (NYSE:BSX) officials said today that renewed strength in its drug-eluting stent business should be enough to offset a weak cardiac rhythm management market over the near term. Speaking at an investors conference in Boston this morning, BSX officials said they expect the U.S. CRM market to be soft for at least the […]

By MassDevice Staff

Devices & Diagnostics

Boston Scientific layoffs hitting Minnesota workforce now

It turns out the rumors were true: Minnesota-based employees of Boston Scientific Corp. (NYSE:BSX) began receiving pink slips this week. Reports surfaced last month that the Natick, Mass.-based medical device giant was planning to lay off workers from its cardiology, rhythm and vascular business in the Twin Cities. The unit, which manufactures pacemakers and implantable […]

By MassDevice Staff

Devices & Diagnostics

Boston Scientific CEO’s base pay doubled, sales down last year

Boston Scientific Corp. CEO Ray Elliott’s base salary gets a bump in 2010, but his total draw falls dramatically from 2009. Boston Scientific Corp. (NYSE:BSX) CEO Raymond Elliott’s salary got a haircut last year, dropping about 23 percent to $4.9 million during 2010. It was widely reported in media outlets last year that 61-year-old Elliott’s […]

By MassDevice Staff

Devices & Diagnostics

Medical device lawsuit between OrbusNeich, Boston Scientific will continue

A Massachusetts federal judge ruled that two non-patent claims in OrbusNeich Medical Inc.’s infringement lawsuit over Boston Scientific Corp.’s (NYSE:BSX) Liberté stent should not be dismissed for being too old. Judge Richard Stearns of the U.S. District Court for Massachusetts denied Natick, Mass.-based Boston Scientific’s motion for a summary judgment on OrbusNeich’s claims for breach […]

By MassDevice Staff

Health IT

Boston Sci exec takes over Twin Cities-based BridgePoint Medical

Denis Harrington, who until recently was head of sales for Boston Scientific Corp.'s cardiovascular and CRM business, has left the company to become president and CEO of a Twin Cities startup called BridgePoint Medical Inc.

Devices & Diagnostics

BSX restructuring forces every manager to focus on ‘driving value’

Boston Scientific Corp. (NYSE:BSX) is shedding more light on a top-down restructuring that has seen it re-align or replace more than 75 percent of its top 50 senior managers in the past year. “We’ve spent a lot of time thinking about what the senior management team needs to be,” BSX CFO Jeff Capello said at […]

By MassDevice Staff

Devices & Diagnostics

March Madness: many Duke basketball fans at Medtronic, Boston Scientific

They go head-to-head in just about everything else, but it's likely that the brass at Boston Scientific and Medtronic both have the Blue Devils going all the way in March Madness. Medtronic Inc. (NYSE:MDT) and Boston Scientific Corp. (NYSE:BSX) share a more than healthy rivalry when it comes to stents, pacemakers and other cardiovascular devices, but when it comes to basketball, it's all Duke baby! That's because the Dukies literally infest the front offices and boardrooms of the two medical device giants.

By MassDevice Staff

Devices & Diagnostics

Boston Scientific, St. Jude Medical agree to settle court case

Boston Scientific Corp. (NYSE:BSX) and St. Jude Medical Inc. (NYSE:STJ) agreed to settle a breach of contract case involving a former Guidant Corp. sales rep who allegedly tried to lure his former colleagues to St. Jude.

By MassDevice Staff

Health Services

Maximize Revenue and Patient Care with Strategic Weight Loss Management

We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.

By Build My Health and MedCity News

Devices & Diagnostics

Boston Scientific Omega stent now selling in Europe

Boston Scientific Corp.'s (NYSE:BSX) third-generation stent platform, the platinum-chromium Omega bare-metal stent, won CE Mark approval in the European Union. Boston Scientific said it plans to make the device available "immediately" in the EU and other countries that recognize the mark. It's the first of a trio of stents the Natick, Mass.-based medical device maker plans to launch on the platform, according to a press release.

By MassDevice Staff

Devices & Diagnostics

Boston Scientific layoffs coming in cardiology medical device area

Boston Scientific layoffs will come from its cardiology, rhythm and vascular unit. Executives at BSX told employees that the cuts were coming so the medical company in Massachusetts could remain competitive.

By MassDevice Staff

Devices & Diagnostics

Medical device maker Boston Scientific shares rise after rating boost

Boston Scientific Corp.'s stock jumps as much as 6 percent after RBC Capital Markets boosts its rating of the medical device maker's stock.

By MassDevice Staff

Devices & Diagnostics

Boston Scientific pacemaker subsidiary dodges class-action suit again

A federal judge in California dismissed for the second time a purported class-action lawsuit against Boston Scientific's star-crossed Guidant Corp. pacemaker subsidiary.

By MassDevice Staff

Devices & Diagnostics

Boston Scientific to sell market-leading stents in India

The Natick, Mass.-based medical device giant said it's launching the third generation of its market-leading Promus and Taxus drug-eluting stents in a country of more than 1.1 billion people. Company officials say the DES market in India is surging, with an estimated 150,000 stents implanted annually. BSX won regulatory approval for the devices in India last year.

By MassDevice Staff